Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Actinogen Medical ( (AU:ACW) ) has provided an announcement.
Actinogen Medical has announced accelerated enrolment in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim analysis scheduled for January 2026 and final results expected in mid-Q4 2026. The company also reported a successful meeting with the FDA, paving the way for a streamlined path to marketing approval and enhancing its potential for partnerships. Additionally, Actinogen has launched an Investor Hub to engage shareholders and successfully completed a pharmacokinetic trial confirming the efficacy of Xanamem’s commercial formulation. These developments signify significant progress in Actinogen’s clinical and commercial strategies, potentially strengthening its position in the Alzheimer’s treatment market.
More about Actinogen Medical
Actinogen Medical is a biotechnology company focused on developing innovative treatments for neurological conditions, particularly Alzheimer’s disease. The company’s primary product, Xanamem, is aimed at treating Alzheimer’s by targeting elevated levels of the blood biomarker pTau181, which is associated with disease progression.
Average Trading Volume: 2,700,350
Technical Sentiment Signal: Hold
Current Market Cap: A$98.44M
See more data about ACW stock on TipRanks’ Stock Analysis page.